Pink SheetPwC: Regulatory, Policy Uncertainty Constrain Dealmaking Life sciences deal volume and total valuation has been sluggish approaching the midpoint of 2025, even compared to the below-average numbers p
ScripWoodcock: Don’t Do The Wrong Study, Even If FDA Tells You To Janet Woodcock said she has told drug developers not to blindly follow agency advice, an unusual comment from a former US Food and Drug Adm
ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti
In VivoRising Leader 2025 recipient June Lanoue’s interest in science and health care took root at an early age. “I had human anatomy books when I was a little kid,” she shared. “My parents would yell at me